{"id":44599,"date":"2010-04-29T09:59:46","date_gmt":"2010-04-29T13:59:46","guid":{"rendered":"\/gazette\/?p=44599"},"modified":"2019-06-26T13:42:58","modified_gmt":"2019-06-26T17:42:58","slug":"peering-into-gearworks-of-fda","status":"publish","type":"post","link":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","title":{"rendered":"Peering into gearworks of FDA"},"content":{"rendered":"\n\t
\"\"

\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d says author and Harvard professor Daniel Carpenter. \n<\/p>

Jon Chase\/Harvard Staff Photographer<\/p><\/figcaption><\/figure>\n\n\t

\n\t\t\t\n\t\t\tArts & Culture\t\t<\/a>\n\t\t\n\t\t

\n\t\tPeering into gearworks of FDA\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\t

\n\t\tSarah Sweeney\t<\/p>\n\t\t\t

\n\t\t\tHarvard Staff Writer\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t

\n\t\t\tHarvard author examines federal agency too often labeled simply \u2018great or horrible\u2019\t\t<\/h2>\n\t\t\n<\/header>\n\n\n\n
\n\n\n\t\t

Topping off at 800 pages, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA<\/a>\u201d is Daniel Carpenter\u2019s opus.<\/p>\n

Carpenter, the Allie S. Freed Professor of Government and director of the Center for American Political Studies, became fascinated with the Food and Drug Administration<\/a> (FDA)\u00a020 years ago \u201cbecause the agency was always in the news and because its decisions were so controversial at the same time that the agency was so highly respected in scientific and popular circles.\u201d<\/p>\n

But Carpenter said the research on the FDA then was \u201cincredibly simplistic. In these works, the FDA is either great or it\u2019s horrible; it\u2019s either purely altruistic or it\u2019s power-hungry. A number of well-informed scholars and careful observers of the agency told me the same thing: namely, that previous treatments had oversimplified the agency. I wanted to step outside of those binary narratives.\u201d<\/p>\n

One of his approaches was examining the FDA\u2019s reputation. \u201cA big part of the FDA\u2019s power comes from the way it is viewed by different audiences,\u201d said Carpenter. \u201cSo I spent a lot of time not only in the records and archives of the FDA, but in the records of medical associations and researchers, drug companies, research hospitals like Mayo Clinic and M.D. Anderson, European and Indian drug regulators and health agencies, politicians, and Supreme Court justices, social movement organizations, and interest groups.\u201d<\/p>\n

Behind the scenes, much of what happens at \u201cresearch universities around the world is dependent upon FDA rules, regulations, and discussions,\u201d said Carpenter.<\/p>\n

But what about the American people? Have they become disillusioned by dodgy pharmaceuticals and lawsuits?<\/p>\n

\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d he noted.<\/p>\n

\u201cThe most vivid event in building this reputation was FDA officer Frances Kelsey\u2019s\u00a0refusal to let thalidomide on the U.S. market,\u201d he said. \u201cWhen that drug was marketed in Europe and Australia, thousands of children were born with irreversible birth defects, and there were uncounted stillbirths and abortions.\u201d (Kelsey\u2019s photo is on the cover of the book.)<\/p>\n

\u201cThe general public does, on the whole, trust the FDA, though not as much as it used to,\u201d said Carpenter, who believes the next five to 10 years will be critical for the agency.<\/p>\n

\u201cReputation and Power\u201d also chronicles pivotal FDA decisions, from the 1980s AIDS crisis to oral contraceptives, to chemotherapy, to phased trials and manufacturing.<\/p>\n

\u201cThis has been 12 years, over 100 archival collections, and three continents of research in the making,\u201d said Carpenter. \u201cI think my proudest moment came when Richard Merrill, a former FDA general counsel and the nation\u2019s top legal scholar on drug regulation \u2014 and a tough critic \u2014 told me that the book was the best treatment of new drug regulation he had ever seen. From someone who lived it and studied it for decades, that was a nice endorsement.\u201d<\/p>\n\n\n<\/div>\n\n\t\t","protected":false},"excerpt":{"rendered":"

Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.<\/p>\n","protected":false},"author":105622744,"featured_media":44833,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"gz_ga_pageviews":0,"gz_ga_lastupdated":"","document_color_palette":"crimson","author":"Sarah Sweeney","affiliation":"Harvard Staff Writer","_category_override":"","_yoast_wpseo_primary_category":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1360],"tags":[2021,6203,6998,7504,7893,9787,13115,13504,14784,15447,16519,16998,17031,21340,23305,23445,26425,27388,29171,33407],"gazette-formats":[],"series":[],"class_list":["post-44599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-arts-humanities","tag-reputation-and-power-organizational-image-and-pharmaceutical-regulation-at-the-fda","tag-book","tag-cancer","tag-center-for-american-political-studies","tag-chemotherapy","tag-daniel-carpenter","tag-fda-officer-frances-kelsey","tag-food-and-drug-administration","tag-government","tag-harvard-bound","tag-health","tag-history","tag-hivaids","tag-law","tag-mayo-clinic","tag-medicine","tag-oral-contraceptives","tag-pharmaceuticals","tag-research","tag-thalidomide"],"yoast_head":"\nPeering into gearworks of FDA — Harvard Gazette<\/title>\n<meta name=\"description\" content=\"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peering into gearworks of FDA — Harvard Gazette\" \/>\n<meta property=\"og:description\" content=\"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Harvard Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2010-04-29T13:59:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-06-26T17:42:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"605\" \/>\n\t<meta property=\"og:image:height\" content=\"403\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"harvardgazette\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\"},\"author\":{\"name\":\"harvardgazette\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b\"},\"headline\":\"Peering into gearworks of FDA\",\"datePublished\":\"2010-04-29T13:59:46+00:00\",\"dateModified\":\"2019-06-26T17:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\"},\"wordCount\":543,\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\",\"keywords\":[\"\u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA\u201d\",\"Book\",\"Cancer\",\"Center for American Political Studies\",\"Chemotherapy\",\"Daniel Carpenter\",\"FDA Officer Frances Kelsey\",\"Food and Drug Administration\",\"Government\",\"Harvard Bound\",\"Health\",\"History\",\"HIV\/AIDS\",\"Law\",\"Mayo Clinic\",\"Medicine\",\"Oral Contraceptives\",\"Pharmaceuticals\",\"Research\",\"thalidomide\"],\"articleSection\":[\"Arts & Culture\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2010\",\"copyrightHolder\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\",\"name\":\"Peering into gearworks of FDA — Harvard Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\",\"datePublished\":\"2010-04-29T13:59:46+00:00\",\"dateModified\":\"2019-06-26T17:42:58+00:00\",\"description\":\"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\",\"width\":605,\"height\":403},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"name\":\"Harvard Gazette\",\"description\":\"Official news from Harvard University covering innovation in teaching, learning, and research\",\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\",\"name\":\"The Harvard Gazette\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"width\":164,\"height\":64,\"caption\":\"The Harvard Gazette\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b\",\"name\":\"harvardgazette\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peering into gearworks of FDA — Harvard Gazette","description":"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","og_locale":"en_US","og_type":"article","og_title":"Peering into gearworks of FDA — Harvard Gazette","og_description":"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.","og_url":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","og_site_name":"Harvard Gazette","article_published_time":"2010-04-29T13:59:46+00:00","article_modified_time":"2019-06-26T17:42:58+00:00","og_image":[{"width":605,"height":403,"url":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","type":"image\/jpeg"}],"author":"harvardgazette","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#article","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/"},"author":{"name":"harvardgazette","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b"},"headline":"Peering into gearworks of FDA","datePublished":"2010-04-29T13:59:46+00:00","dateModified":"2019-06-26T17:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/"},"wordCount":543,"publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","keywords":["\u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA\u201d","Book","Cancer","Center for American Political Studies","Chemotherapy","Daniel Carpenter","FDA Officer Frances Kelsey","Food and Drug Administration","Government","Harvard Bound","Health","History","HIV\/AIDS","Law","Mayo Clinic","Medicine","Oral Contraceptives","Pharmaceuticals","Research","thalidomide"],"articleSection":["Arts & Culture"],"inLanguage":"en-US","copyrightYear":"2010","copyrightHolder":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"}},{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","url":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","name":"Peering into gearworks of FDA — Harvard Gazette","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/#website"},"primaryImageOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","datePublished":"2010-04-29T13:59:46+00:00","dateModified":"2019-06-26T17:42:58+00:00","description":"Daniel Carpenter\u2019s new book, \u201cReputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,\u201d probes the workings of a crucial federal safety agency that often is either lionized or demonized.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/#primaryimage","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","width":605,"height":403},{"@type":"WebSite","@id":"https:\/\/news.harvard.edu\/gazette\/#website","url":"https:\/\/news.harvard.edu\/gazette\/","name":"Harvard Gazette","description":"Official news from Harvard University covering innovation in teaching, learning, and research","publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/news.harvard.edu\/gazette\/#organization","name":"The Harvard Gazette","url":"https:\/\/news.harvard.edu\/gazette\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","width":164,"height":64,"caption":"The Harvard Gazette"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b","name":"harvardgazette"}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Peering into gearworks of FDA","url":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2010\/04\/peering-into-gearworks-of-fda\/"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg?w=150","image":{"@type":"ImageObject","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg"},"articleSection":"Arts & Culture","author":[{"@type":"Person","name":"harvardgazette"}],"creator":["harvardgazette"],"publisher":{"@type":"Organization","name":"Harvard Gazette","logo":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg"},"keywords":["\u201creputation and power: organizational image and pharmaceutical regulation at the fda\u201d","book","cancer","center for american political studies","chemotherapy","daniel carpenter","fda officer frances kelsey","food and drug administration","government","harvard bound","health","history","hiv\/aids","law","mayo clinic","medicine","oral contraceptives","pharmaceuticals","research","thalidomide"],"dateCreated":"2010-04-29T13:59:46Z","datePublished":"2010-04-29T13:59:46Z","dateModified":"2019-06-26T17:42:58Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Peering into gearworks of FDA\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2010\\\/04\\\/peering-into-gearworks-of-fda\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2010\\\/04\\\/peering-into-gearworks-of-fda\\\/\"},\"thumbnailUrl\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2010\\\/04\\\/042610_carpenter_155_605.jpg?w=150\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2010\\\/04\\\/042610_carpenter_155_605.jpg\"},\"articleSection\":\"Arts & Culture\",\"author\":[{\"@type\":\"Person\",\"name\":\"harvardgazette\"}],\"creator\":[\"harvardgazette\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Harvard Gazette\",\"logo\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Harvard_Gazette_logo.svg\"},\"keywords\":[\"\\u201creputation and power: organizational image and pharmaceutical regulation at the fda\\u201d\",\"book\",\"cancer\",\"center for american political studies\",\"chemotherapy\",\"daniel carpenter\",\"fda officer frances kelsey\",\"food and drug administration\",\"government\",\"harvard bound\",\"health\",\"history\",\"hiv\\\/aids\",\"law\",\"mayo clinic\",\"medicine\",\"oral contraceptives\",\"pharmaceuticals\",\"research\",\"thalidomide\"],\"dateCreated\":\"2010-04-29T13:59:46Z\",\"datePublished\":\"2010-04-29T13:59:46Z\",\"dateModified\":\"2019-06-26T17:42:58Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/news.harvard.edu\/p.js"},"jetpack_featured_media_url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","has_blocks":true,"block_data":{"0":{"blockName":"harvard-gazette\/article-header","attrs":{"blockColorPalette":"","coloredHeading":"","creditText":"Jon Chase\/Harvard Staff Photographer","displayDetails":"","displayTitle":"","categoryId":1360,"mediaAlt":"","mediaCaption":"\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d says author and Harvard professor Daniel Carpenter. \n","mediaId":44833,"mediaSize":"full","mediaType":"image","mediaUrl":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg","poster":"","title":"Peering into gearworks of FDA","subheading":"Harvard author examines federal agency too often labeled simply \u2018great or horrible\u2019","centeredImage":true,"className":"is-style-full-width-text-below","mediaHeight":403,"mediaWidth":605,"backgroundFixed":false,"backgroundTone":"light","coloredBackground":false,"displayOverlay":true,"fadeInText":false,"isAmbient":false,"mediaLength":"","mediaPosition":"","posterText":"","titleAbove":false,"useUncroppedImage":false,"lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"<figure class=\"wp-block-image\"><img alt=\"\" height=\"403\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\" width=\"605\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--caption\">\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d says author and Harvard professor Daniel Carpenter. \n<\/p><p class=\"wp-element-caption--credit\">Jon Chase\/Harvard Staff Photographer<\/p><\/figcaption><\/figure>\n","innerContent":["<figure class=\"wp-block-image\"><img alt=\"\" height=\"403\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\" width=\"605\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--caption\">\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d says author and Harvard professor Daniel Carpenter. \n<\/p><p class=\"wp-element-caption--credit\">Jon Chase\/Harvard Staff Photographer<\/p><\/figcaption><\/figure>\n"],"rendered":"<header\n\tclass=\"wp-block-harvard-gazette-article-header alignfull article-header is-style-full-width-text-below centered-image\"\n\tstyle=\" \"\n>\n\t<figure class=\"wp-block-image\"><img alt=\"\" height=\"403\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2010\/04\/042610_carpenter_155_605.jpg\" width=\"605\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--caption\">\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d says author and Harvard professor Daniel Carpenter. \n<\/p><p class=\"wp-element-caption--credit\">Jon Chase\/Harvard Staff Photographer<\/p><\/figcaption><\/figure>\n\n\t<div class=\"article-header__content\">\n\t\t\t<a\n\t\t\tclass=\"article-header__category\"\n\t\t\thref=\"https:\/\/news.harvard.edu\/gazette\/section\/arts-humanities\/\"\n\t\t>\n\t\t\tArts & Culture\t\t<\/a>\n\t\t\n\t\t<h1 class=\"article-header__title wp-block-heading \">\n\t\tPeering into gearworks of FDA\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t<div class=\"article-header__meta\">\n\t\t<div class=\"wp-block-post-author\">\n\t\t\t<address class=\"wp-block-post-author__content\">\n\t\t\t\t\t<p class=\"author wp-block-post-author__name\">\n\t\tSarah Sweeney\t<\/p>\n\t\t\t<p class=\"wp-block-post-author__byline\">\n\t\t\tHarvard Staff Writer\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t<time class=\"article-header__date\" datetime=\"2010-04-29\">\n\t\t\tApril 29, 2010\t\t<\/time>\n\n\t\t<span class=\"article-header__reading-time\">\n\t\t\t3 min read\t\t<\/span>\n\t<\/div>\n\n\t\n\t\t\t<h2 class=\"article-header__subheading wp-block-heading\">\n\t\t\tHarvard author examines federal agency too often labeled simply \u2018great or horrible\u2019\t\t<\/h2>\n\t\t\n<\/header>\n"},"2":{"blockName":"core\/group","attrs":{"templateLock":false,"metadata":{"name":"Article content"},"align":"wide","layout":{"type":"constrained","justifyContent":"center"},"tagName":"div","lock":[],"className":"","style":[],"backgroundColor":"","textColor":"","gradient":"","fontSize":"","fontFamily":"","borderColor":"","ariaLabel":"","anchor":""},"innerBlocks":[{"blockName":"core\/freeform","attrs":{"content":"","lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"\n\t\t<p>Topping off at 800 pages, \u201c<a href=\"http:\/\/press.princeton.edu\/titles\/9205.html\">Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA<\/a>\u201d is Daniel Carpenter\u2019s opus.<\/p>\n<p>Carpenter, the Allie S. Freed Professor of Government and director of the Center for American Political Studies, became fascinated with the <a href=\"http:\/\/www.fda.gov\/\">Food and Drug Administration<\/a> (FDA)\u00a020 years ago \u201cbecause the agency was always in the news and because its decisions were so controversial at the same time that the agency was so highly respected in scientific and popular circles.\u201d<\/p>\n<p>But Carpenter said the research on the FDA then was \u201cincredibly simplistic. In these works, the FDA is either great or it\u2019s horrible; it\u2019s either purely altruistic or it\u2019s power-hungry. A number of well-informed scholars and careful observers of the agency told me the same thing: namely, that previous treatments had oversimplified the agency. I wanted to step outside of those binary narratives.\u201d<\/p>\n<p>One of his approaches was examining the FDA\u2019s reputation. \u201cA big part of the FDA\u2019s power comes from the way it is viewed by different audiences,\u201d said Carpenter. \u201cSo I spent a lot of time not only in the records and archives of the FDA, but in the records of medical associations and researchers, drug companies, research hospitals like Mayo Clinic and M.D. Anderson, European and Indian drug regulators and health agencies, politicians, and Supreme Court justices, social movement organizations, and interest groups.\u201d<\/p>\n<p>Behind the scenes, much of what happens at \u201cresearch universities around the world is dependent upon FDA rules, regulations, and discussions,\u201d said Carpenter.<\/p>\n<p>But what about the American people? Have they become disillusioned by dodgy pharmaceuticals and lawsuits?<\/p>\n<p>\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d he noted.<\/p>\n<p>\u201cThe most vivid event in building this reputation was FDA officer Frances Kelsey\u2019s\u00a0refusal to let thalidomide on the U.S. market,\u201d he said. \u201cWhen that drug was marketed in Europe and Australia, thousands of children were born with irreversible birth defects, and there were uncounted stillbirths and abortions.\u201d (Kelsey\u2019s photo is on the cover of the book.)<\/p>\n<p>\u201cThe general public does, on the whole, trust the FDA, though not as much as it used to,\u201d said Carpenter, who believes the next five to 10 years will be critical for the agency.<\/p>\n<p>\u201cReputation and Power\u201d also chronicles pivotal FDA decisions, from the 1980s AIDS crisis to oral contraceptives, to chemotherapy, to phased trials and manufacturing.<\/p>\n<p>\u201cThis has been 12 years, over 100 archival collections, and three continents of research in the making,\u201d said Carpenter. \u201cI think my proudest moment came when Richard Merrill, a former FDA general counsel and the nation\u2019s top legal scholar on drug regulation \u2014 and a tough critic \u2014 told me that the book was the best treatment of new drug regulation he had ever seen. From someone who lived it and studied it for decades, that was a nice endorsement.\u201d<\/p>\n","innerContent":["\n\t\t<p>Topping off at 800 pages, \u201c<a href=\"http:\/\/press.princeton.edu\/titles\/9205.html\">Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA<\/a>\u201d is Daniel Carpenter\u2019s opus.<\/p>\n<p>Carpenter, the Allie S. Freed Professor of Government and director of the Center for American Political Studies, became fascinated with the <a href=\"http:\/\/www.fda.gov\/\">Food and Drug Administration<\/a> (FDA)\u00a020 years ago \u201cbecause the agency was always in the news and because its decisions were so controversial at the same time that the agency was so highly respected in scientific and popular circles.\u201d<\/p>\n<p>But Carpenter said the research on the FDA then was \u201cincredibly simplistic. In these works, the FDA is either great or it\u2019s horrible; it\u2019s either purely altruistic or it\u2019s power-hungry. A number of well-informed scholars and careful observers of the agency told me the same thing: namely, that previous treatments had oversimplified the agency. I wanted to step outside of those binary narratives.\u201d<\/p>\n<p>One of his approaches was examining the FDA\u2019s reputation. \u201cA big part of the FDA\u2019s power comes from the way it is viewed by different audiences,\u201d said Carpenter. \u201cSo I spent a lot of time not only in the records and archives of the FDA, but in the records of medical associations and researchers, drug companies, research hospitals like Mayo Clinic and M.D. Anderson, European and Indian drug regulators and health agencies, politicians, and Supreme Court justices, social movement organizations, and interest groups.\u201d<\/p>\n<p>Behind the scenes, much of what happens at \u201cresearch universities around the world is dependent upon FDA rules, regulations, and discussions,\u201d said Carpenter.<\/p>\n<p>But what about the American people? Have they become disillusioned by dodgy pharmaceuticals and lawsuits?<\/p>\n<p>\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d he noted.<\/p>\n<p>\u201cThe most vivid event in building this reputation was FDA officer Frances Kelsey\u2019s\u00a0refusal to let thalidomide on the U.S. market,\u201d he said. \u201cWhen that drug was marketed in Europe and Australia, thousands of children were born with irreversible birth defects, and there were uncounted stillbirths and abortions.\u201d (Kelsey\u2019s photo is on the cover of the book.)<\/p>\n<p>\u201cThe general public does, on the whole, trust the FDA, though not as much as it used to,\u201d said Carpenter, who believes the next five to 10 years will be critical for the agency.<\/p>\n<p>\u201cReputation and Power\u201d also chronicles pivotal FDA decisions, from the 1980s AIDS crisis to oral contraceptives, to chemotherapy, to phased trials and manufacturing.<\/p>\n<p>\u201cThis has been 12 years, over 100 archival collections, and three continents of research in the making,\u201d said Carpenter. \u201cI think my proudest moment came when Richard Merrill, a former FDA general counsel and the nation\u2019s top legal scholar on drug regulation \u2014 and a tough critic \u2014 told me that the book was the best treatment of new drug regulation he had ever seen. From someone who lived it and studied it for decades, that was a nice endorsement.\u201d<\/p>\n"],"rendered":"\n\t\t<p>Topping off at 800 pages, \u201c<a href=\"http:\/\/press.princeton.edu\/titles\/9205.html\">Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA<\/a>\u201d is Daniel Carpenter\u2019s opus.<\/p>\n<p>Carpenter, the Allie S. Freed Professor of Government and director of the Center for American Political Studies, became fascinated with the <a href=\"http:\/\/www.fda.gov\/\">Food and Drug Administration<\/a> (FDA)\u00a020 years ago \u201cbecause the agency was always in the news and because its decisions were so controversial at the same time that the agency was so highly respected in scientific and popular circles.\u201d<\/p>\n<p>But Carpenter said the research on the FDA then was \u201cincredibly simplistic. In these works, the FDA is either great or it\u2019s horrible; it\u2019s either purely altruistic or it\u2019s power-hungry. A number of well-informed scholars and careful observers of the agency told me the same thing: namely, that previous treatments had oversimplified the agency. I wanted to step outside of those binary narratives.\u201d<\/p>\n<p>One of his approaches was examining the FDA\u2019s reputation. \u201cA big part of the FDA\u2019s power comes from the way it is viewed by different audiences,\u201d said Carpenter. \u201cSo I spent a lot of time not only in the records and archives of the FDA, but in the records of medical associations and researchers, drug companies, research hospitals like Mayo Clinic and M.D. Anderson, European and Indian drug regulators and health agencies, politicians, and Supreme Court justices, social movement organizations, and interest groups.\u201d<\/p>\n<p>Behind the scenes, much of what happens at \u201cresearch universities around the world is dependent upon FDA rules, regulations, and discussions,\u201d said Carpenter.<\/p>\n<p>But what about the American people? Have they become disillusioned by dodgy pharmaceuticals and lawsuits?<\/p>\n<p>\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d he noted.<\/p>\n<p>\u201cThe most vivid event in building this reputation was FDA officer Frances Kelsey\u2019s\u00a0refusal to let thalidomide on the U.S. market,\u201d he said. \u201cWhen that drug was marketed in Europe and Australia, thousands of children were born with irreversible birth defects, and there were uncounted stillbirths and abortions.\u201d (Kelsey\u2019s photo is on the cover of the book.)<\/p>\n<p>\u201cThe general public does, on the whole, trust the FDA, though not as much as it used to,\u201d said Carpenter, who believes the next five to 10 years will be critical for the agency.<\/p>\n<p>\u201cReputation and Power\u201d also chronicles pivotal FDA decisions, from the 1980s AIDS crisis to oral contraceptives, to chemotherapy, to phased trials and manufacturing.<\/p>\n<p>\u201cThis has been 12 years, over 100 archival collections, and three continents of research in the making,\u201d said Carpenter. \u201cI think my proudest moment came when Richard Merrill, a former FDA general counsel and the nation\u2019s top legal scholar on drug regulation \u2014 and a tough critic \u2014 told me that the book was the best treatment of new drug regulation he had ever seen. From someone who lived it and studied it for decades, that was a nice endorsement.\u201d<\/p>\n"}],"innerHTML":"\n<div class=\"wp-block-group alignwide\">\n\n\n\n<\/div>\n","innerContent":["\n<div class=\"wp-block-group alignwide\">\n\n","\n\n<\/div>\n"],"rendered":"\n<div class=\"wp-block-group alignwide has-global-padding is-content-justification-center is-layout-constrained wp-block-group-is-layout-constrained\">\n\n\n\t\t<p>Topping off at 800 pages, \u201c<a href=\"http:\/\/press.princeton.edu\/titles\/9205.html\">Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA<\/a>\u201d is Daniel Carpenter\u2019s opus.<\/p>\n<p>Carpenter, the Allie S. Freed Professor of Government and director of the Center for American Political Studies, became fascinated with the <a href=\"http:\/\/www.fda.gov\/\">Food and Drug Administration<\/a> (FDA)\u00a020 years ago \u201cbecause the agency was always in the news and because its decisions were so controversial at the same time that the agency was so highly respected in scientific and popular circles.\u201d<\/p>\n<p>But Carpenter said the research on the FDA then was \u201cincredibly simplistic. In these works, the FDA is either great or it\u2019s horrible; it\u2019s either purely altruistic or it\u2019s power-hungry. A number of well-informed scholars and careful observers of the agency told me the same thing: namely, that previous treatments had oversimplified the agency. I wanted to step outside of those binary narratives.\u201d<\/p>\n<p>One of his approaches was examining the FDA\u2019s reputation. \u201cA big part of the FDA\u2019s power comes from the way it is viewed by different audiences,\u201d said Carpenter. \u201cSo I spent a lot of time not only in the records and archives of the FDA, but in the records of medical associations and researchers, drug companies, research hospitals like Mayo Clinic and M.D. Anderson, European and Indian drug regulators and health agencies, politicians, and Supreme Court justices, social movement organizations, and interest groups.\u201d<\/p>\n<p>Behind the scenes, much of what happens at \u201cresearch universities around the world is dependent upon FDA rules, regulations, and discussions,\u201d said Carpenter.<\/p>\n<p>But what about the American people? Have they become disillusioned by dodgy pharmaceuticals and lawsuits?<\/p>\n<p>\u201cFor the audience of the mass public, the FDA\u2019s reputation is compelling because people believe that the agency has kept them safe, and that the FDA generally \u2018gets it right,\u2019\u201d he noted.<\/p>\n<p>\u201cThe most vivid event in building this reputation was FDA officer Frances Kelsey\u2019s\u00a0refusal to let thalidomide on the U.S. market,\u201d he said. \u201cWhen that drug was marketed in Europe and Australia, thousands of children were born with irreversible birth defects, and there were uncounted stillbirths and abortions.\u201d (Kelsey\u2019s photo is on the cover of the book.)<\/p>\n<p>\u201cThe general public does, on the whole, trust the FDA, though not as much as it used to,\u201d said Carpenter, who believes the next five to 10 years will be critical for the agency.<\/p>\n<p>\u201cReputation and Power\u201d also chronicles pivotal FDA decisions, from the 1980s AIDS crisis to oral contraceptives, to chemotherapy, to phased trials and manufacturing.<\/p>\n<p>\u201cThis has been 12 years, over 100 archival collections, and three continents of research in the making,\u201d said Carpenter. \u201cI think my proudest moment came when Richard Merrill, a former FDA general counsel and the nation\u2019s top legal scholar on drug regulation \u2014 and a tough critic \u2014 told me that the book was the best treatment of new drug regulation he had ever seen. From someone who lived it and studied it for decades, that was a nice endorsement.\u201d<\/p>\n\n\n<\/div>\n"}},"jetpack-related-posts":[{"id":58155,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2002\/11\/prying-the-lid-off-the-fda\/","url_meta":{"origin":44599,"position":0},"title":"Prying the lid off the FDA","author":"harvardgazette","date":"November 14, 2002","format":false,"excerpt":"Even though asthma is responsible for more deaths and more hospitalizations than arthritis in the United States, the greater political influence of arthritis sufferers prompts the federal Food and Drug Administration to work more expeditiously on their behalf. \"Why give one drug priority over another?\" asks researcher Daniel Carpenter. \"Well,\u2026","rel":"","context":"In "Science & Tech"","block_context":{"text":"Science & Tech","link":"https:\/\/news.harvard.edu\/gazette\/section\/science-technology\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":16493,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2002\/11\/prying-the-lid-off-the-fda-2\/","url_meta":{"origin":44599,"position":1},"title":"Prying the lid off the FDA:","author":"gazetteimport","date":"November 14, 2002","format":false,"excerpt":"Why does the Food and Drug Administration (FDA) take longer to approve asthma medicines than arthritis medicines?","rel":"","context":"In "Campus & Community"","block_context":{"text":"Campus & Community","link":"https:\/\/news.harvard.edu\/gazette\/section\/campus-community\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":87493,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2011\/08\/ten-professors-named-cabot-fellows\/","url_meta":{"origin":44599,"position":2},"title":"Ten professors named Cabot Fellows","author":"harvardgazette","date":"August 9, 2011","format":false,"excerpt":"Ten professors in Harvard\u2019s Faculty of Arts and Sciences have been named Walter Channing Cabot Fellows.","rel":"","context":"In "Campus & Community"","block_context":{"text":"Campus & Community","link":"https:\/\/news.harvard.edu\/gazette\/section\/campus-community\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2011\/08\/120710_blair_ann_106_605.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2011\/08\/120710_blair_ann_106_605.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2011\/08\/120710_blair_ann_106_605.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":42384,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2004\/01\/newsmakers-46\/","url_meta":{"origin":44599,"position":3},"title":"Newsmakers","author":"gazetteimport","date":"January 22, 2004","format":false,"excerpt":"Design by Silvetti, Machado receives BSA award","rel":"","context":"In "Campus & Community"","block_context":{"text":"Campus & Community","link":"https:\/\/news.harvard.edu\/gazette\/section\/campus-community\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":5198,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2008\/04\/fda-deadlines-may-compromise-drug-safety-by-rushing-approvals\/","url_meta":{"origin":44599,"position":4},"title":"FDA deadlines may compromise drug safety by rushing approvals","author":"harvardgazette","date":"April 3, 2008","format":false,"excerpt":"Many medications are approved by the U.S. Food and Drug Administration (FDA) on the brink of congressionally mandated deadlines, and those drugs are more likely to face later regulatory intervention than those approved with greater deliberation, researchers at Harvard University have found. Drugs fast-tracked by the FDA are more likely\u2026","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":275259,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/05\/harvard-faculty-behind-fda-course-discusses-high-rx-prices\/","url_meta":{"origin":44599,"position":5},"title":"Tackling high Rx prices","author":"Lian Parsons","date":"May 17, 2019","format":false,"excerpt":"The HarvardX online platform is offering a free course on the FDA and prescription drug prices. Three faculty members behind the course discuss the issues.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"four people talking outside the Harvard Ed Portal building","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/050819_prescrip_05372500.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/050819_prescrip_05372500.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/050819_prescrip_05372500.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/050819_prescrip_05372500.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/44599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/users\/105622744"}],"replies":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/comments?post=44599"}],"version-history":[{"count":1,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/44599\/revisions"}],"predecessor-version":[{"id":279614,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/44599\/revisions\/279614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media\/44833"}],"wp:attachment":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media?parent=44599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/categories?post=44599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/tags?post=44599"},{"taxonomy":"format","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/gazette-formats?post=44599"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/series?post=44599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}